Patent intelligence · CN
CN 1284066
Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
Patent details — CN 1284066
- Jurisdiction
- CN
- Status
- expired
- Grant date
- Feb 14, 2001
- Expiration
- Feb 9, 2021
- Applicant
- ALLERGEN SALES INC [US]
- CPC classes
- A61K 31/ 415 A I, A61K 31/ 497 A I, A61K 31/ 4164 A I, A61K 31/ 4178 A I
Quick answer
CN 1284066 (Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors) is held by ALLERGEN SALES INC [US]. Status: expired. Granted Feb 14, 2001. Expires Feb 9, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGEN SALES INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 415 A I, A61K 31/ 497 A I, A61K 31/ 4164 A I, A61K 31/ 4178 A I, A61K 31/ 4725 A I, A61K31/415
More from ALLERGEN SALES INC [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
granted -
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
granted
Frequently asked questions
What is US patent 1284066?
CN 1284066 (Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors) is held by ALLERGEN SALES INC [US]. Status: expired. Granted Feb 14, 2001. Expires Feb 9, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CN 1284066?
ALLERGEN SALES INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does CN 1284066 expire?
Our index shows an expiration date of Feb 9, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.